AKYA Quote, Financials, Valuation and Earnings

Bionano Genomics has a net margin of -94.07% compared to Akoya Biosciences's net margin of -48.04%. Akoya Biosciences's return on equity of -338.02% beat Bionano Genomics's return on equity of -141.6%.

Akoya Biosciences has a consensus price target of $1.88, signalling upside risk potential of 48.23%. On the other hand Bionano Genomics has an analysts' consensus of $7.33 which suggests that it could grow by 94.52%. Given that Bionano Genomics has higher upside potential than Akoya Biosciences, analysts believe Bionano Genomics is more attractive than Akoya Biosciences.

Akoya Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.367, suggesting its more volatile than the S&P 500 by 136.713%.

Akoya Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akoya Biosciences pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Akoya Biosciences quarterly revenues are $16.6M, which are larger than Bionano Genomics quarterly revenues of $6.5M. Akoya Biosciences's net income of -$15.7M is lower than Bionano Genomics's net income of -$3.1M. Notably, Akoya Biosciences's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akoya Biosciences is 0.79x versus 0.16x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -94.07% compared to Akoya Biosciences's net margin of 2.17%. Akoya Biosciences's return on equity of -338.02% beat Bruker's return on equity of 4.53%.

Akoya Biosciences has a consensus price target of $1.88, signalling upside risk potential of 48.23%. On the other hand Bruker has an analysts' consensus of $55.13 which suggests that it could grow by 48.4%. Given that Bruker has higher upside potential than Akoya Biosciences, analysts believe Bruker is more attractive than Akoya Biosciences.

Akoya Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bruker has a beta of 1.228, suggesting its more volatile than the S&P 500 by 22.782%.

Akoya Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.54% to investors and pays a quarterly dividend of $0.05 per share. Akoya Biosciences pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Akoya Biosciences quarterly revenues are $16.6M, which are smaller than Bruker quarterly revenues of $801.4M. Akoya Biosciences's net income of -$15.7M is lower than Bruker's net income of $17.4M. Notably, Akoya Biosciences's price-to-earnings ratio is -- while Bruker's PE ratio is 71.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akoya Biosciences is 0.79x versus 1.63x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -94.07% compared to Akoya Biosciences's net margin of -231.19%. Akoya Biosciences's return on equity of -338.02% beat Harvard Bioscience's return on equity of -103.83%.

Akoya Biosciences has a consensus price target of $1.88, signalling upside risk potential of 48.23%. On the other hand Harvard Bioscience has an analysts' consensus of $3.00 which suggests that it could grow by 703.64%. Given that Harvard Bioscience has higher upside potential than Akoya Biosciences, analysts believe Harvard Bioscience is more attractive than Akoya Biosciences.

Akoya Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.441, suggesting its more volatile than the S&P 500 by 44.128%.

Akoya Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akoya Biosciences pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Akoya Biosciences quarterly revenues are $16.6M, which are smaller than Harvard Bioscience quarterly revenues of $21.8M. Akoya Biosciences's net income of -$15.7M is higher than Harvard Bioscience's net income of -$50.3M. Notably, Akoya Biosciences's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akoya Biosciences is 0.79x versus 0.18x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -94.07% compared to Akoya Biosciences's net margin of -67.73%. Akoya Biosciences's return on equity of -338.02% beat Quanterix's return on equity of -14.39%.

Akoya Biosciences has a consensus price target of $1.88, signalling upside risk potential of 48.23%. On the other hand Quanterix has an analysts' consensus of $11.25 which suggests that it could grow by 121.24%. Given that Quanterix has higher upside potential than Akoya Biosciences, analysts believe Quanterix is more attractive than Akoya Biosciences.

Akoya Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Quanterix has a beta of 1.116, suggesting its more volatile than the S&P 500 by 11.641%.

Akoya Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akoya Biosciences pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Akoya Biosciences quarterly revenues are $16.6M, which are smaller than Quanterix quarterly revenues of $30.3M. Akoya Biosciences's net income of -$15.7M is higher than Quanterix's net income of -$20.5M. Notably, Akoya Biosciences's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akoya Biosciences is 0.79x versus 1.46x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.